

BELLICUM PHARMACEUTICALS, INC
 Form 4
 December 23, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 McGuyer Frank B.

(Last) (First) (Middle)

C/O BELLICUM
 PHARMACEUTICALS, INC., 2130
 W. HOLCOMBE BLVD., STE. 800

(Street)

HOUSTON, TX 77030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 BELLICUM
 PHARMACEUTICALS, INC
 [BLCM]

3. Date of Earliest Transaction
 (Month/Day/Year)
 12/23/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	12/23/2014		C		298,434 (1) (2)	A (3)	445,492	I	By McGuyer Investments Ltd.
Common Stock	12/23/2014		C		1,227,132 (1) (2)	A (4)	1,672,624	I	By McGuyer Investments Ltd.
	12/23/2014		C			A (5)	1,974,466	I	

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

Common Stock				301,842 <u>(1) (2)</u>					By McGuyer Investments Ltd.
Common Stock	12/23/2014		C	196,197 <u>(1) (2)</u>	A	<u>(5)</u>	2,170,663	I	By McGuyer Investments Ltd.
Common Stock	12/23/2014		J <u>(6)</u>	44,735 <u>(1)</u>	A	\$ 0	2,215,398	I	By McGuyer Investments Ltd.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series A Convertible Preferred Stock	<u>(3)</u>	12/23/2014		C	507,339 <u>(1)</u>	<u>(3)</u> <u>(3)</u>	<u>(3)</u> <u>(3)</u>	Common Stock	298,4 <u>(1) (2)</u>
Series B Convertible Preferred Stock	<u>(4)</u>	12/23/2014		C	2,086,125 <u>(1)</u>	<u>(4)</u> <u>(4)</u>	<u>(4)</u> <u>(4)</u>	Common Stock	1,227, <u>(1) (2)</u>
Series C Convertible Preferred Stock	<u>(5)</u>	12/23/2014		C	513,133 <u>(1)</u>	<u>(5)</u> <u>(5)</u>	<u>(5)</u> <u>(5)</u>	Common Stock	301,8 <u>(1) (2)</u>
Series C Convertible Preferred Stock	<u>(5)</u>	12/23/2014		C	333,536 <u>(1)</u>	<u>(5)</u> <u>(5)</u>	<u>(5)</u> <u>(5)</u>	Common Stock	196,1 <u>(1) (2)</u>

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
McGuyer Frank B. C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030	X			

Signatures

/s/ Frank B.
McGuyer
12/23/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person has voting and investment power held by McGuyer Investments Ltd. The Reporting Person disclaims beneficial
- (1) ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
 - (2) Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014.
 - (3) The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
 - (4) The Series B Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
 - (5) The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
- On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B
- (6) Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.